Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 12/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 12/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5265789 | 0.87 | ALOX5AP (0.33) | KCNH2BRD4MAPT | |
| SCHEMBL5230010 | 0.85 | PDE4A (0.36) | PDCD1CD274LMNAL3MBTL1PDE4A | |
| SCHEMBL5227829 | 0.83 | GRIN1 (0.32) | BRD4MAPT | |
| SCHEMBL4163017 | 0.81 | KCNH2 (0.36) | KCNH2BRD4 | |
| SCHEMBL5266946 | 0.80 | PDE1A (0.31) | BRD4 | |
| SCHEMBL4765982 | 0.80 | ALDH1A1 (0.33) | KCNH2BRD4 | |
| SCHEMBL4764107 | 0.80 | ALDH1A1 (0.33) | KCNH2BRD4 | |
| SCHEMBL5263590 | 0.80 | — | — | |
| SCHEMBL5886357 | 0.79 | BRD4 (0.33) | KCNH2BRD4MAPT | |
| SCHEMBL5266948 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1619948-A4 | SUSTITUTED IMIDAZOLOPYRAZINE AND TRIAZOLOPYRAZINE DERIVATIVES: GABAA RECEPTOR LIGANDS | NEUROGEN CORP (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20060247245-A1 | Substituted imidazolopyrazine and triazolopyrazine derivatives: gabaa receptor ligands | NEUROGEN CORPORATION | 2006-11-02 | — | — | US | disclosed |
| EP-1619948-A1 | SUSTITUTED IMIDAZOLOPYRAZINE AND TRIAZOLOPYRAZINE DERIVATIVES: GABAA RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004107863-A1 | SUSTITUTED IMIDAZOLOPYRAZINE AND TRIAZOLOPYRAZINE DERIVATIVES: GABAA RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247245-A1 | Substituted imidazolopyrazine and triazolopyrazine derivatives: gabaa receptor ligands | GABRA5, GABRA3, GABRA2 | PDCD1 2624/4885CD274 2537/4885KCNH2 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.